NasalFent gives earlier pain relief than IRMS

UK speciality drugmaker Archimedes Pharma released strong Phase III trial data for NasalFent, its fentanyl citrate nasal spray for the rapid  relief of breakthrough cancer pain. The expanded results from the 044  study demonstrate that NasalFent is superior to immediate release  morphine sulphate, the most commonly prescribed medicine for this  indication.

NasalFent was proven to provide significantly earlier pain relief than  IRMS, an important factor for breakthrough cancer pain patients, who  need rapid relief from these debilitating pain episodes.

Breakthrough cancer pain affects up to 95% of all cancer patients and is  characterized by sudden, unpredictable episodes of intense pain that  occur despite background medication. NasalFent produced a statistically  significantly greater number of pain episodes treated with NasalFent  showed onset of effect within five minutes (p<0.05) and  clinically-meaningful pain relief within 10 minutes (p<0.05).